An FDA advisory panel is supporting an earlier administration of the pneumonia vaccine. Prevnar 13 is to prevent pneumococcal disease–which is a bacteria causing pneumonia and other invasive disease.
The advisory panel is poised to suggest the Prevnar 13 be given to adults older than 50.
This vaccine is routinely suggested for those under age 65 with risk factors (like diabetes, asthma or chronic lung disease), but until now has not been suggested for the routine population until age 65. There is a study with more than 85,000 adults being held now to confirm the results.
I’ll keep you posted.